EC News DeskAllurion, the world’s first and only weight loss device that requires no surgery, endoscopy, or anaesthesia, announced a major update to the Allurion Virtual Care Suite. These two features – the Allurion Iris Artificial Intelligence Platform and Success Predictor, are the first in a pipeline of machine-learning algorithms designed to improve patient outcomes. Starting today, the Success Predictor is available to all Allurion partner clinics across the UAE.
The Success Predictor is a proprietary machine-learning algorithm trained on millions of data points from more than 20,000 Allurion Balloon Program patients in over 50 different countries, to ensure a high degree of useful data generated. This feature can inform the clinic if the patient is on track or not to reach their minimum expected weight loss, as early as 20 days into the program. Through early identification of patients needing additional support, clinicians can intervene sooner, enabling them to course correct the patient’s care, quickly getting them back on track.
Based on the AI Platform, the Success Predictor can detect if patients are on track to meet their goals
Allurion’s Co-founder and CEO, Shantanu Gaur, MD, said: “Allurion is fully committed to giving our customers powerful tools to turbocharge their care delivery and leverage the power of data to take the Allurion Program to the next level. We believe that the future of weight loss will be an ecosystem comprised of multiple modalities of therapy. These new features to the Virtual Care Suite uniquely position it to be the ideal choice for providers all over the world to manage their patients and improve outcomes.”
The Success Predictor is just one of several new features that are announced as part of a major update to the VCS. In addition, through the introduction of Treatment Tracking and Clinic-Led Onboarding, the VCS now enables seamless management of patients undergoing one or multiple weight-loss treatments including gastric balloons, surgery, or medications.
